AAVANTGARDE BIO

aavantgarde-bio-logo

AAVantgarde Bio is developing gene therapies for inherited retinal disorders.

#SimilarOrganizations #People #Financial #Website #More

AAVANTGARDE BIO

Industry:
Biotechnology Health Care Therapeutics

Founded:
2021-01-01

Address:
Milano, Lombardia, Italy

Country:
Italy

Website Url:
http://www.aavantgardebio.com

Status:
Active

Email Addresses:
[email protected]

Total Funding:
0

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Mobile Non Scaleable Content


Similar Organizations

chimeron-bio-logo

Chimeron Bio

Chimeron Bio develops agents for personalized cancer gene therapy.


Current Advisors List

paola-pozzi_image

Paola Pozzi Board Member @ AAVantgarde Bio
Board_member

Founder


not_available_image

Alberto Auricchio

Investors List

sofinnova-partners_image

Sofinnova Partners

Sofinnova Partners investment in Seed Round - AAVantgarde Bio

Official Site Inspections

http://www.aavantgardebio.com

  • Host name: 104.17.17.9
  • IP address: 104.17.17.9
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "AAVantgarde Bio"

AAVantgarde - Pioneers in cutting-edge AAV technology

AAVantgarde is a clinical stage, Italian-headquartered international biotechnology company with two proprietary AAV platforms for large-gene deliverySee details»

AAVantgarde Bio - Crunchbase Company Profile

Organization. AAVantgarde Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number +39 329-552-4297; AAVantgarde …See details»

About us - AAVantgarde

Our platforms (dual hybrid and intein-mediated) are being validated in two inherited retinal diseases (IRDs) with a high unmet need: Usher syndrome type 1B (USH1B) and Stargardt disease (STGD) respectively and have the …See details»

Our team - About us - AAVantgarde

AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field …See details»

AAVantgarde Bio - PitchBook

AAVantgarde Bio General Information Description. Developer of a gene therapy biotechnology company designed for inherited retinal disorders. The company's technology builds on proprietary Adeno-Associated Viral (AAV) vector …See details»

AAVantgarde Bio - LinkedIn

AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA ...See details»

AAVantgarde Bio - Forbion

Www.aavantgardebio.com Via Vincenzo Gioberti, 8 20123 Milano Worked on by. Dmitrij Hristodorov, PhD General Partner. Dmitrij Hristodorov joined Forbion in March 2020 Read more Tim Lohoff , PhD Senior Associate. Tim is a Senior …See details»

AAVantgarde Bio - Products, Competitors, Financials, Employees ...

AAVantgarde Bio is a clinical-stage biotechnology company focused on developing proprietary adeno-associated viral (AAV) vector platforms within the biotechnology sector. Use the CB …See details»

AAVantgarde Closes €61 Million Series A Financing to …

Jun 6, 2023 AAVantgarde has two proprietary, AAV-based large gene delivery platforms: one leveraging DNA recombination, named dual hybrid; and one protein trans-splicing, named AAV intein.See details»

AAVantgarde Bio - VentureRadar

"AAVantgarde Bio is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene …See details»

A large international investment in hereditary retinal …

Jun 6, 2023 The path of AAVantgarde Bio, the Tigem spin-off dedicated to the development of gene therapies for hereditary diseases of the retina, continues at full speed! The company, founded in 2021 thanks to the Sofinnova-Telethon …See details»

AAVantgarde Closes €61 Million Series A Financing to Advance …

Jun 6, 2023 - Financing led by Atlas Venture and Forbion - Company created, incubated and seed financed by Sofinnova Partners MILAN, Italy, June 06, 2023 (GLOBE NEWSWIRE) -- …See details»

TIGEM's Startup, AAVantgarde Bio, Emerges as Gene Therapy …

May 27, 2024 ©2024 TIGEM - Telethon Institute of Genetics and Medicine | Via Campi Flegrei, 34 | 80078 Pozzuoli (NA), ItalySee details»

AAVantgarde closes €61 million Series A financing to advance two ...

Jun 6, 2023 For more information, please visit: www.aavantgardebio.com. About Atlas Venture. Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing …See details»

AAVantgarde Closes €61 Million Series A Financing to

Jun 6, 2023 For more information, please visit: www.aavantgardebio.com. About Atlas Venture Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing …See details»

AAVantgarde appoints Ram Palanki as Chairman of its Board of …

AAVantgarde is an innovative biotechnology start-up, co-founded by Dr. Alberto Auricchio and born from the research activities carried out at Tigem (Telethon Institute of Genetics and …See details»

AAVantgarde Bio Appoints Dr. Natalia Misciattelli as Chief …

Sep 8, 2022 AAVantgarde Bio, a clinical stage Milan-based international biotechnology start-up that has developed proprietary Adeno-Associated Viral (AAV) vector platforms that allow for …See details»

AAVantgarde Bio - VentureRadar

Similar Companies: Scout Bio USA Privately Held Scout Bio is a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major …See details»

Longwood Fund - AAVantgarde Bio

AAVantgarde Bio is a clinical stage, Italian headquartered, international biotechnology company that has developed two proprietary Adeno-Associated Viral (AAV) vector platforms to address …See details»

Innovation - AAVantgarde

Pipeline. The company is validating its proprietary platforms in two lead programs in Ophthalmology with a high unmet need: Usher Syndrome Type 1B-associated retinitis …See details»

linkstock.net © 2022. All rights reserved